Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.
2.

Cellular Stress Response to Varicella-Zoster Virus Infection of Human Skin Includes Highly Elevated Interleukin-6 Expression.

Jarosinski KW, Carpenter JE, Buckingham EM, Jackson W, Knudtson K, Moffat JF, Kita H, Grose C.

Open Forum Infect Dis. 2018 May 22;5(6):ofy118. doi: 10.1093/ofid/ofy118. eCollection 2018 Jun.

3.

Targeting the alternative sigma factor RpoN to combat virulence in Pseudomonas aeruginosa.

Lloyd MG, Lundgren BR, Hall CW, Gagnon LB, Mah TF, Moffat JF, Nomura CT.

Sci Rep. 2017 Oct 3;7(1):12615. doi: 10.1038/s41598-017-12667-y.

4.

Erratum for Sarwar et al., GcsR, a TyrR-Like Enhancer-Binding Protein, Regulates Expression of the Glycine Cleavage System in Pseudomonas aeruginosa PAO1.

Sarwar Z, Lundgren BR, Grassa MT, Wang MX, Gribble M, Moffat JF, Nomura CT.

mSphere. 2016 Jul 27;1(4). pii: e00200-16. doi: 10.1128/mSphere.00200-16. eCollection 2016 Jul-Aug.

5.

GcsR, a TyrR-Like Enhancer-Binding Protein, Regulates Expression of the Glycine Cleavage System in Pseudomonas aeruginosa PAO1.

Sarwar Z, Lundgren BR, Grassa MT, Wang MX, Gribble M, Moffat JF, Nomura CT.

mSphere. 2016 Apr 27;1(2). pii: e00020-16. doi: 10.1128/mSphere.00020-16. eCollection 2016 Mar-Apr. Erratum in: mSphere. 2016 Jul-Aug;1(4). pii: e00200-16. doi: 10.1128/mSphere.00200-16.

6.

β-l-1-[5-(E-2-bromovinyl)-2-(hydroxymethyl)-1,3-(dioxolan-4-yl)] uracil (l-BHDU) prevents varicella-zoster virus replication in a SCID-Hu mouse model and does not interfere with 5-fluorouracil catabolism.

De C, Liu D, Zheng B, Singh US, Chavre S, White C, Arnold RD, Hagen FK, Chu CK, Moffat JF.

Antiviral Res. 2014 Oct;110:10-9. doi: 10.1016/j.antiviral.2014.07.007. Epub 2014 Jul 19.

7.

Varicella-zoster virus. Preface.

Abendroth A, Arvin AM, Moffat JF.

Curr Top Microbiol Immunol. 2010;342:v-vi. No abstract available.

PMID:
20973159
8.

Effects of varicella-zoster virus on cell cycle regulatory pathways.

Moffat JF, Greenblatt RJ.

Curr Top Microbiol Immunol. 2010;342:67-77. doi: 10.1007/82_2010_28. Review.

PMID:
20397072
9.

Varicella-zoster virus T cell tropism and the pathogenesis of skin infection.

Arvin AM, Moffat JF, Sommer M, Oliver S, Che X, Vleck S, Zerboni L, Ku CC.

Curr Top Microbiol Immunol. 2010;342:189-209. doi: 10.1007/82_2010_29. Review.

10.

Compounds that target host cell proteins prevent varicella-zoster virus replication in culture, ex vivo, and in SCID-Hu mice.

Rowe J, Greenblatt RJ, Liu D, Moffat JF.

Antiviral Res. 2010 Jun;86(3):276-85. doi: 10.1016/j.antiviral.2010.03.007. Epub 2010 Mar 20.

11.

Analysis of the functions of glycoproteins E and I and their promoters during VZV replication in vitro and in skin and T-cell xenografts in the SCID mouse model of VZV pathogenesis.

Arvin AM, Oliver S, Reichelt M, Moffat JF, Sommer M, Zerboni L, Berarducci B.

Curr Top Microbiol Immunol. 2010;342:129-46. doi: 10.1007/82_2009_1. Review.

PMID:
20186616
12.

Cyclin-dependent kinase 1/cyclin B1 phosphorylates varicella-zoster virus IE62 and is incorporated into virions.

Leisenfelder SA, Kinchington PR, Moffat JF.

J Virol. 2008 Dec;82(24):12116-25. doi: 10.1128/JVI.00153-08. Epub 2008 Sep 17.

13.

Varicella-zoster virus infection of human fibroblast cells activates the c-Jun N-terminal kinase pathway.

Zapata HJ, Nakatsugawa M, Moffat JF.

J Virol. 2007 Jan;81(2):977-90. Epub 2006 Nov 1.

15.

Replication of varicella-zoster virus in human skin organ culture.

Taylor SL, Moffat JF.

J Virol. 2005 Sep;79(17):11501-6.

16.

Human cytomegalovirus genes in the 15-kilobase region are required for viral replication in implanted human tissues in SCID mice.

Wang W, Taylor SL, Leisenfelder SA, Morton R, Moffat JF, Smirnov S, Zhu H.

J Virol. 2005 Feb;79(4):2115-23.

17.

Viral and cellular kinases are potential antiviral targets and have a central role in varicella zoster virus pathogenesis.

Moffat JF, McMichael MA, Leisenfelder SA, Taylor SL.

Biochim Biophys Acta. 2004 Mar 11;1697(1-2):225-31. Review.

PMID:
15023363
18.

Roscovitine, a cyclin-dependent kinase inhibitor, prevents replication of varicella-zoster virus.

Taylor SL, Kinchington PR, Brooks A, Moffat JF.

J Virol. 2004 Mar;78(6):2853-62.

19.

Varicella-zoster virus gE escape mutant VZV-MSP exhibits an accelerated cell-to-cell spread phenotype in both infected cell cultures and SCID-hu mice.

Santos RA, Hatfield CC, Cole NL, Padilla JA, Moffat JF, Arvin AM, Ruyechan WT, Hay J, Grose C.

Virology. 2000 Sep 30;275(2):306-17.

20.

Development of recombinant varicella-zoster virus vaccines.

Arvin AM, Mallory S, Moffat JF.

Contrib Microbiol. 1999;3:193-200. Review. No abstract available.

PMID:
10599531
21.

The ORF47 and ORF66 putative protein kinases of varicella-zoster virus determine tropism for human T cells and skin in the SCID-hu mouse.

Moffat JF, Zerboni L, Sommer MH, Heineman TC, Cohen JI, Kaneshima H, Arvin AM.

Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11969-74.

22.
23.

Varicella-zoster virus: aspects of pathogenesis and host response to natural infection and varicella vaccine.

Arvin AM, Moffat JF, Redman R.

Adv Virus Res. 1996;46:263-309. Review.

PMID:
8824702
24.
25.

Effects of an isogenic Zn-metalloprotease-deficient mutant of Legionella pneumophila in a guinea-pig pneumonia model.

Moffat JF, Edelstein PH, Regula DP Jr, Cirillo JD, Tompkins LS.

Mol Microbiol. 1994 Jun;12(5):693-705.

PMID:
8052122
26.
27.

Supplemental Content

Loading ...
Support Center